Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

Acta Oncol. 2010;49(1):110-3. doi: 10.3109/02841860903104152.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Benzimidazoles / adverse effects*
  • Enzyme Inhibitors / adverse effects
  • Humans
  • MAP Kinase Kinase 1 / antagonists & inhibitors
  • MAP Kinase Kinase Kinase 2 / antagonists & inhibitors
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Skin Diseases / chemically induced*

Substances

  • AZD 6244
  • Antineoplastic Agents
  • Benzimidazoles
  • Enzyme Inhibitors
  • MAP Kinase Kinase Kinase 2
  • MAP Kinase Kinase 1